
Johnson & Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.
The Johnson & Johnson Analyst: Analyst Asad Haider maintained a Buy rating and price target of $185.